Prime Medicine gains after winning arbitration with Beam Therapeutics
Seeking Alpha ·
Prime Medicine ( PRME ) added ~8% in the premarket on Wednesday after an arbitration tribunal sided with the gene editing company in connection with a previously disclosed dispute with its rival Beam Therapeutics ( BEAM ).
DYAX Investor Sentiment
Bullish (Long) 47% · Bearish (Short) 53%
505 participants
Related News
- Fervo Energy surges as faster Cape Station drilling seen lowering cost concerns
- Applied Materials CEO says AI investment splurge might extend longer than expected
- Vermilion receives TSX spproval for new share buyback program
- The US dollar breaks out of the pattern it was stuck in
- Global Battery Electric Vehicle Market Report Now Available; Profiles Tesla, BYD, and 33 Other Key Players
- AMD Tops $900 Billion Market Capitalization Again — Can It Follow Micron To $1 Trillion Valuation?